The IKBIP Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung carcinoma epithelial cell line. This product features targeted disruption of the IKBIP gene, encoding the inhibitor of kappa B kinase-interacting protein, a critical modulator of NF-??B signaling and apoptosis. The polyclonal knockout format provides a heterogeneous pool of cells harboring loss-of-function mutations introduced via CRISPR/Cas9-mediated gene editing, offering a versatile model without clonal selection. This population is ideal for studying IKBIP function in a physiologically relevant lung adenocarcinoma context.
The A-549 cell line, established from lung adenocarcinoma tissue, exhibits adherent epithelial morphology and serves as a principal model for lung adenocarcinoma research. These cells express alveolar epithelial markers and respond to cytokines, making them suitable for studying oncogenic signaling and apoptosis. Their well-characterized genetic background and wild-type TP53 status facilitate investigations into tumor suppressor networks and drug response mechanisms in non-small-cell lung cancer. A-549 cells provide a clinically relevant context for knockout studies exploring NF-??B pathway alterations.
IKBIP acts as a negative regulator of canonical NF-??B signaling by binding directly to IKBKB (IKK??) and preventing phosphorylation and degradation of NFKBIA (I??B??). This interaction retains NF-??B dimers, such as RELA/p50, in the cytoplasm, repressing transcription of pro-survival and inflammatory genes. IKBIP expression is regulated upstream by TP53 and TNF-??, while it influences downstream anti-apoptotic factors BCL2L1 (Bcl-xL) and BIRC5 (Survivin). IKBIP also interacts with IKBKG (NEMO) as part of the IKK complex, which includes CHUK and NFKB1, positioning it centrally in the NF-??B pathway. Disruption of IKBIP relieves IKBKB inhibition, leading to constitutive NF-??B activation and enhanced cell survival.
In A-549 lung adenocarcinoma cells, IKBIP knockout generates a loss-of-function model that accentuates NF-??B-dependent survival signaling. Aberrant NF-??B activation is prevalent in lung adenocarcinoma, driving proliferation, metastasis, and drug resistance. By eliminating IKBIP, this cell population enables investigation of enhanced NF-??B activity on tumorigenic phenotypes, including apoptotic resistance and growth advantages. Since A-549 cells retain wild-type TP53, the model is particularly valuable for dissecting the regulatory interplay between TP53 and IKBIP in modulating NF-??B responses. This system also facilitates studies on therapeutic resistance mechanisms involving the IKK?CNF-??B axis.
The IKBIP Knockout A-549 Polyclonal Cells support diverse experimental workflows. NF-??B signaling status can be assessed via western blotting for phospho-IKBKB and NFKBIA degradation, and NF-??B reporter assays quantify transcriptional output. Apoptosis sensitivity is evaluated using Annexin V staining, while proliferation assays measure cell growth changes. RNA-seq enables transcriptome-wide analysis of gene expression alterations driven by constitutive NF-??B activity. These applications make the product suitable for research on NF-??B signaling, apoptosis regulation, lung cancer biology, and drug resistance. For more information, please contact Ascent Research.
